High-dose Interferon Alpha in Treatment of Patients with Malignant Melanoma, Monitoring of Predictive and Prognostic Biomarkers

Česká verzia

Authors: J. Vaňásková; J. Grim; J. Kopecký; E. Kubala; S. Filip
Authors place of work: Klinika onkologie a radioterapie, LF UK a FN Hradec Králové
Published in the journal: Klin Onkol 2011; 24(3): 180-186
Category: Reviews

Summary

Backrounds:
The incidence of malignant melanoma is increasing by about 2–5% per year, exceeding an incidence of all other tumors. Adjuvant immunotherapy with high-dose interferon (HDI) as per the ECOG 1684 trial Kirkwood’s schema is still recommended as a standard. HDI should be started within 60 days after a surgical procedure. Meaningful adjuvant immunotherapy is based on radical surgical excision, an investigation of the sentinel node and regional lymph node dissection, if indicated. Current research aims to utilize routinely usable biomarkers in order to define patients who would explicitly profit from HDI.

Design:
The authors present a review of HDI trials, focusing on the management of adverse effects of HDI and on biomarkers. This review also discusses the initial own experiences at the Oncology Centre in Hradec Králové.

Conclusion:
Malignant melanoma is a very immunogenic tumour. Immunotherapy with HDI is considered to be the only therapeutic modality so far that has been proven to prolong relapse-free survival and overall survival (in short-time criterion) in adjuvant setting. However, the results of these trials are inconsistent and particular biomarkers of therapeutic response have not been defined yet.

Key words:
malignant melanoma – immunotherapy – high-dose interferon – prognostic and predictive factors – serum VEGF

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. Dušek L, Mužík J, Gelnarová E. Incidence a mortalita nádorových onemocnění v České republice. Klin Onkol 2010; 23(5): 311–324.

2. Eggermont A, Garde C, Peris K et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 2010; 46(2): 270–283.

3. Krajsová I. Mapování a biopsie sentinelové uzliny. In: Krajsová I (ed). Melanom. Praha: Maxdorf 2006: 155–170.

4. Verma S, Quirt I, McCready D et al. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106(7): 1431–1442.

5. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14(1): 7–17.

6. Crott R. Cost effectiveness and cost utility of adjuvant interferon alpha in cutaneous melanoma: a review. Pharmacoeconomics 2004; 22(9): 569–580.

7. Gogas H, Pectasides D, Kirkwood JM. et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354(7): 709–718.

8. Hořejší V, Bartůňková J. Cytokiny. Základy imunologie. 4. vydání. Praha: Triton 2009: 101–112.

9. Kirkwood JM, Wang W, Edington HD et al. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res 2008; 14(24): 8314–8320.

10. KopeckýJ, Kopecký O. NK buňky, chemokiny a chemokinové receptory. Klin Onkol 2010; 23(1): 1–9.

11. Abuzahra F, Baron JM, Heise R et al. Adjuvant interferon alfa treatment in patients with malignant melanoma stimulates transporter proteins associated with antigen processing and proteasome activator 28. Lancet Oncol 2004; 5(4): 250.

12. Svane IM, Trepiakas R, Pedersen AE et al. Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine 2009; 27(16): 2213–2219.

13. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon alfa2b in high risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18(12): 2444–2458.

14. Kirkwood JM, Lee S, Tarhini AA et al. Prognostic significance of serum S100B protein in high-rish surgically resected melanoma patients participating in Intergroup trial ECOG 1694. J Clin Oncol 2009; 27(1): 38–44.

15. Kirkwood JM, Manola J, Ibrahim J et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10(1): 1670–1677.

16. Eggermont AM. The role interferon-alfa in malignant melanoma remains to be defined. Eur J Cancer 2001; 37(17): 2147–2153.

17. Eggermont AM, Gogas H, Testori A et al. Utility of systemic adjuvant therapy in melanoma. Ann Oncol 2009; 20 (Suppl 6): vi30–vi34.

18. Eggermont AM, Bouwhuis MG, Suciu S et al. Autoimmune antibodies in recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst 2009; 101(12): 869–877.

19. Mohr P, Weichenthal M, Hauschild A. Adjuvant therapy in melanoma. Onkologie 2003; 26(3): 227–233.

20. Slaton JW, Perrotte P, Inoue K et al. Interferon-alfa-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5(10): 2726–2734.

21. Chiaron-Sileni V, Del Bianco P, Romanini A et al. Tolerability of intensified interferon-alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Melanoma Inter-group trial (IMI – Mel.A.) ISRCTN75125874. BMC Cancer 2006; 6: 44.

22. Kirkwood JM. Studies of interferons in the therapy of melanoma. Semin Oncol 1991; 18(5 Suppl 7): 83–90.

23. Agarwala SS, Gray RJ, Wong MK. Duration of high-dose interferon alfa-2b for resected high-risk melanoma.J Clin Oncol 2009; 27(25): e82–e83.

24. Gogas H, Pectasides D, Dafni U et al. A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon-alfa2b in patients with resected high risk melanoma. J Clin Oncol 2009; 27(6): 939–944.

25. Bédane C, Le Brun V, Boulinguez S et al. Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon alpha. Ann Dermatol Venereol 1999; 126(2): 142–146.

26. Auyeung SF, Long Q, Royster EB et al. Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy. Clin Trials 2009; 6(5): 480–490.

27. Aquilar García G, Serrano Falcón C, Serrano Falcón Mdel M et al. Cutaneous necrosis due to interferon alpha in a patient with melanoma. Actas Dermosifiliogr 2006; 97(8): 539–542.

28. Filip S, Mokrý J, Petera J. Kmenové buňky, nádorové kmenové buňky a karcinogeneze. Klin Onkol 2006; 19(2): 149–152.

29. Larrivée B, Karsan A. Signalling pathways induced by vascular endothelial growth factor (review). Int J Mol Med 2000; 5(5): 447–456.

30. Ciotti P, Rainero ML, Nicolò G et al. Cytokine expression in human primary and metastatic melanoma cells: analysis in fresh bioptic specimens. Melanoma Res 1995; 5(1): 41–47.

31. Mouawad R, Rixe O, Meric JB et al. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther 2002; 7(4): 151–156.

32. Kirkwood JM, Tarhini AA, Moschos SJ et al. Adjuvant therapy with high-dose interferon alfa-2b in patients with high-risk stage IIB/III melanoma. Nat Clin Pract Oncol 2008; 5(1): 2–3.

33. Kirkwood JM, Edington HD, Marrangoni AM et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alfa2b. Clin Cancer Res 2007; 13(8): 2422–2428.

34. Cormier NJ, Xing Y, Ding M et al. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol 2007; 25(17): 2442–2448.

35. Kefford RF. Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol 2003; 14(3): 358–365.

36. Moschos SJ, Kirkwood JM, Konstantinopoulos PA. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol 2004; 22(1): 11–14.

37. Bedikian AY, Kim KB, Legha SS et al. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res 2009; 19(1): 42–49.

38. Falkson CI. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma. Med Oncol 1995; 12(1): 35–40.

39. Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1998; 16(5):1743–1751.

40. Letzel S, Fierlbeck G, Voelter-Mahlknecht S et al. Phase 2 trial of the continuous IV administration of interferon-beta in patients with disseminated malignant melanoma. Skinmed 2006; 5(6): 271–276.

41. Kirkwood JM, Moschos SJ, Edington HD et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular response. J Clin Oncol 2006; 24(19): 3164–3171.